Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2004 2
2005 1
2006 1
2009 1
2012 2
2014 2
2016 2
2021 1
2022 2
2023 2
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Bisphosphonates for osteoporosis in people with cystic fibrosis.
Jeffery TC, Chang AB, Conwell LS. Jeffery TC, et al. Cochrane Database Syst Rev. 2023 Jan 10;1(1):CD002010. doi: 10.1002/14651858.CD002010.pub5. Cochrane Database Syst Rev. 2023. PMID: 36625789 Free PMC article.
BACKGROUND: Osteoporosis is a disorder of bone mineralisation occurring in about one third of adults with cystic fibrosis. ...This is an updated version of a previous review. OBJECTIVES: To assess the effects of bisphosphonates on the frequency …
BACKGROUND: Osteoporosis is a disorder of bone mineralisation occurring in about one third of adults with cystic fibrosis …
Bisphosphonates for osteoporosis in people with cystic fibrosis.
Conwell LS, Chang AB. Conwell LS, et al. Cochrane Database Syst Rev. 2014 Mar 14;2014(3):CD002010. doi: 10.1002/14651858.CD002010.pub4. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2023 Jan 10;1:CD002010. doi: 10.1002/14651858.CD002010.pub5. PMID: 24627308 Free PMC article. Updated. Review.
BACKGROUND: Osteoporosis is a bone mineralisation disorder occurring in about one third of adults with cystic fibrosis. ...OBJECTIVES: To assess the effects of bisphosphonates on the frequency of fractures, bone mineral density, quality of life, advers …
BACKGROUND: Osteoporosis is a bone mineralisation disorder occurring in about one third of adults with cystic fibrosis. …
Treatment for osteoporosis in people with beta-thalassaemia.
Bhardwaj A, Swe KMM, Sinha NK. Bhardwaj A, et al. Cochrane Database Syst Rev. 2023 May 9;5(5):CD010429. doi: 10.1002/14651858.CD010429.pub3. Cochrane Database Syst Rev. 2023. PMID: 37159055 Free PMC article.
This is an update of a previously published Cochrane Review. OBJECTIVES: To review the evidence on the efficacy and safety of treatment for osteoporosis in people with beta-thalassaemia. ...We recommend further long-term RCTs on different bisphospho …
This is an update of a previously published Cochrane Review. OBJECTIVES: To review the evidence on the efficacy and safety of …
Bisphosphonates for osteoporosis in people with cystic fibrosis.
Conwell LS, Chang AB. Conwell LS, et al. Cochrane Database Syst Rev. 2012 Apr 18;(4):CD002010. doi: 10.1002/14651858.CD002010.pub3. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2014 Mar 14;(3):CD002010. doi: 10.1002/14651858.CD002010.pub4. PMID: 22513903 Updated.
BACKGROUND: Osteoporosis is a bone mineralisation disorder occurring in about one third of adults with cystic fibrosis. ...OBJECTIVES: To assess the effects of bisphosphonates on the frequency of fractures, bone mineral density, quality of life, advers …
BACKGROUND: Osteoporosis is a bone mineralisation disorder occurring in about one third of adults with cystic fibrosis. …
Treatment for osteoporosis in people with ss-thalassaemia.
Bhardwaj A, Swe KM, Sinha NK, Osunkwo I. Bhardwaj A, et al. Cochrane Database Syst Rev. 2016 Mar 10;3:CD010429. doi: 10.1002/14651858.CD010429.pub2. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2023 May 9;5:CD010429. doi: 10.1002/14651858.CD010429.pub3. PMID: 26964506 Updated.
Osteoporosis represents an important cause of morbidity in people with beta-thalassaemia and its pathogenesis is multifactorial. ...OBJECTIVES: To review the evidence on the efficacy and safety of treatment for osteoporosis in people with beta-t …
Osteoporosis represents an important cause of morbidity in people with beta-thalassaemia and its pathogenesis is multifactoria …
Bisphosphonates for osteoporosis in people with cystic fibrosis.
Brenckmann C, Papaioannou A. Brenckmann C, et al. Cochrane Database Syst Rev. 2001;(4):CD002010. doi: 10.1002/14651858.CD002010. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2009 Oct 07;(4):CD002010. doi: 10.1002/14651858.CD002010.pub2. PMID: 11687132 Updated.
OBJECTIVES: To assess the effects of bisphosphonates on the frequency of fractures, bone mineral density, quality of life, adverse events, study withdrawals, and survival in people with cystic fibrosis. SEARCH STRATEGY: Relevant trials were identified …
OBJECTIVES: To assess the effects of bisphosphonates on the frequency of fractures, bone mineral density, quality of life, adverse ev …
Management of osteoporosis in adults with cystic fibrosis.
Hecker TM, Aris RM. Hecker TM, et al. Drugs. 2004;64(2):133-47. doi: 10.2165/00003495-200464020-00002. Drugs. 2004. PMID: 14717616 Review.
Cystic fibrosis (CF) is the most common genetic disease that causes respiratory failure within the Caucasian population. ...Pamidronic acid is beneficial in improving BMD in CF patients before and after transplantation. Bisphosphonate therapy and minimisation …
Cystic fibrosis (CF) is the most common genetic disease that causes respiratory failure within the Caucasian population. ...Pa …
Bisphosphonates for osteoporosis in people with cystic fibrosis.
Conwell LS, Chang AB. Conwell LS, et al. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD002010. doi: 10.1002/14651858.CD002010.pub2. Cochrane Database Syst Rev. 2009. Update in: Cochrane Database Syst Rev. 2012 Apr 18;(4):CD002010. doi: 10.1002/14651858.CD002010.pub3. PMID: 19821288 Updated.
BACKGROUND: Osteoporosis is a bone mineralisation disorder occurring in about one third of adults with cystic fibrosis (CF). Bisphosphonates can increase bone mineral density (BMD) and decrease the risk of new fractures in post-menopausal women and …
BACKGROUND: Osteoporosis is a bone mineralisation disorder occurring in about one third of adults with cystic fibrosis …
Romosozumab used to treat a patient with cystic fibrosis-related osteoporosis.
Crow HM, Graves L, Anabtawi A. Crow HM, et al. Am J Med Sci. 2022 Oct;364(4):461-465. doi: 10.1016/j.amjms.2022.04.018. Epub 2022 Apr 22. Am J Med Sci. 2022. PMID: 35469767 Review.
Bone disease is a known complication of cystic fibrosis (CF). To date, there have been no reports on the effectiveness of romosozumab, monoclonal antibody to sclerostin, to treat CF-related bone disease. ...Of the currently available anti-resorptive or anabolic o …
Bone disease is a known complication of cystic fibrosis (CF). To date, there have been no reports on the effectiveness of romo …
18 results